Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's pelareorep activates interferon (IFN) signalling
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5884)
•••
Comment by Noteableon Dec 25, 2022 1:15pm
131 Views
Post# 35191563

RE:RE:ONCY's pelareorep activates interferon (IFN) signalling

RE:RE:ONCY's pelareorep activates interferon (IFN) signallingBig Biotech/Pharma companies involved in COVID-19 R&D who are increasingly interBig Biotech/Pharma companies involved in COVID-19 R&D who are increasingly interested in ONCY's pelarorep's activation of the IFN signalling pathway and in pelareorp's synergistic capacity as an anti-cancer agent which enhances muliple currently marketed and in development I/O agents, such as immune checkpoint inhibitors, CAR-T therapy, proteosome, PARP and CDK4,6 inhibitors, as examples.

https://www.bio.org/policy/human-health/vaccines-biodefense/coronavirusested in ONCY's pelarorep's activation of the IFN signalling pathway and in pelareorp's synergistic capacity as an anti-cancer agent which enhances muliple currently marketed and in development I/O agents, such as immune checkpoint inhibitors, CAR-T therapy, proteosome, PARP and CDK4,6 inhibitors, as examples.



Biopharmaceutical Innovators Lead the Charge in Fight Against Coronavirus
 
 
 
 
A2A
A2A Pharmaceuticals is testing the use of selective covalent SARS-CoV-2 MPro inhibitors for COVID-19 patients.
Learn more
Therapeutics
Abbott
Abbott has launched its third COVID-19 test, a laboratory-based antibody blood test that will ship in the U.S. beginning in April.
Learn more
Diagnostics
Abbvie
AbbVie has partnered with global authorities to support the use of HIV medicines to treat COVID-19.
Learn more
Therapeutics
Adaptive
Adaptive is leveraging its proprietary immune medicine platform to develop a therapeutic.
Learn more
Therapeutics
Agastiya Biotech
Agastiya Biotech is testing its anti-cancer small molecule AB001 for the treatment of COVID-19. 
Learn more
Therapeutics
Alexion
Alexion has provided SOLIRIS as an experimental emergency treatment for a small number of patients with COVID-19 infection.
Learn more
Therapeutics
Algernon
Algernon is testing Ifenprodil as therapeutic treatment for COVID-19, in addition to acute lung injury (ALI).
Learn more
Therapeutics
Alnylam
Alnylam Pharmaceuticals, Inc. has expanded its collaboration with Vir to advance RNAi therapeutics.
Learn more
Therapeutics
Altimmune
Altimunne is testing a single-dose Intranasal COVID-19 vaccine.
Learn more
Vaccines
Amgen
Amgen is leveraging its immunology and novel antibody therapy development to develop a therapeutic for COVID-19.
Learn more
Therapeutics
APEIRON
APEIRON Biologics AG has initiated a Phase II clinical trial of APN01 to treat COVID-19.
Learn more
Therapeutics
APEPTIC
APEPTICO is researching solnatide IMP for the treatment of coronavirus.
Learn more
Therapeutics
Applied Therapeutics
Applied Therapeutics has launched IND and investigator-initiated studies of AT-001 in critical COVID-19 patients.
Learn more
Therapeutics
Arcturus
Arcturus is developing a COVID-19 candidate vaccine using STARR™ Technology.
Learn more
Vaccines
AstraZeneca
AstraZeneca is assessing the safety, immunogenicity, and efficacy of candidate vaccine AZD1222. 
Learn more
Vaccines
Athersys
Athersys has initiated a clinical trial evaluating MultiStem® cell therapy in patients with COVID-19 induced Acute Respiratory Distress Syndrome.
Learn more
Therapeutics
Bavarian Nordic
Bavarian Nordic has signed an agreement with AdaptVac to license capsid virus like particle (cVLP) technology for coronaviruses.
Learn more
Vaccines
Bayer
Bayer is accelerating the availability of tests and is testing Resochin in treating patients with COVID-19 infection.    
Learn more
Diagnostics
Bellerophon
Bellerophon is testing its INOpulse system to treat the novel coronavirus.
Learn more
Therapeutics
Bharat
Bharat is collaborating with Flugen to develop and test a vaccine against COVID-19 called CoroFlu.
Learn more
Vaccines
BioAegis
BioAegis is testing plasma gelsolin as a therapeutic for coronavirus.
Learn more
Therapeutics
BioCryst
BioCryst has enrolled in a clinical trial to test galidesivir in patients with COVID-19.
Learn more
Therapeutics
Biohaven
Biohaven is beginning the phase 2 trial of intranasal vazegepant to treat lung inflammation after COVID-19 infection.
Learn more
Therapeutics
BioNTech
BioNTech is collaborating with Pfizer by contributing multiple mRNA vaccine candidates as part of its BNT162 COVID-19 vaccine program.
Learn more
Vaccines
CalciMedica
Calcimedica has begun a Phase 2 clinical study of CM4620-IE in patients with severe COVID-19 pneumonia.
Learn more
Therapeutics
Capricor
Capricor has initiated a compassionate use program for severe COVID-19 patients using CAP-1002, its novel cell therapy.
Learn more
Therapeutics
Celularity
Celularity is researching the use of its proprietary CYNK-001 in adults with COVID-19.
Learn more
Therapeutics
Chelation Partners
Chelation Partners is studying the use of DIBI, an Iron-Binding Polymer, as a potential new therapeutic for COVID-19 infections. 
Learn more
Therapeutics
CORNING
Corning partnered with BARDA for the expansion of domestic capacity to manufacture tubing and vials/cartridges.
Learn more
Vaccines
CSL
CSL has formed a partnership and alliance to develop a potential plasma-derived therapy for treating COVID-19.
Learn more
Therapeutics
CureVac
CureVac is focusing on the development of an mRNA-based coronavirus vaccine.
Learn more
Vaccines
Dynavax
Dynavax is providing CpG 1018 to support the development of a COVID-19 vaccine.
Learn more
Vaccines
Eiger
Eiger is evaluating the safety and efficacy of Lambda in patients diagnosed with COVID-19.
Learn more
Therapeutics
Emergent Biosolutions
Emergent Biosolutions is using its proprietary hyperimmune platforms to develop and manufacture plasma-derived therapeutics.
Learn more
Therapeutics
EpiVax
EpiVax is identifying key regions of viral sequences to include in a COVID-19 vaccine.         
Learn more
Vaccines
Flugen
Flugen and Bharat Biotech have begun the development and testing of a unique vaccine against COVID-19 called CoroFlu.
Learn more
Vaccines
Fujifilm
As a total healthcare company, Fujifilm is committed to supporting global efforts to counter the COVID-19 pandemic.
Learn more
Diagnostics
Genentech
Genentech has initiated a Phase III clinical trial of Actemra in hospitalized patients with severe COVID-19 pneumonia.
Learn more
Therapeutics
Generex
Generex has been working to develop a peptide vaccine against the new coronavirus SARS-CoV-2.
Learn more
Vaccines
GeoVax
GeoVax is using its GV-MVA-VLP vaccine platform to develop a vaccine for COVID-19.
Learn more
Vaccines
Gilead
Gilead has initiated two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir. 
Learn more
Therapeutics
Grifols
Grifols has shared technology in convalescent plasma and is working on diagnostic and screening tests.    
Learn more
Diagnostics
GSK
GSK is supplying vaccine adjuvant technology to scientists and organizations working on a vaccine.
Learn more
Vaccines
Humanigen
Humanigen is evaluating lenzilumab for the prevention and treatment of cytokine storm arising from COVID-19.
Learn more
Therapeutics
iBio
iBio has developed SARS-CoV-2 Virus-Like Particle (“VLP”) using its FastPharming System™.
Learn more
Vaccines
IMV
IMV Inc. is developing a vaccine candidate against COVID-19 based on its DPX delivery platform.
Learn more
Vaccines
Incyte
Incyte has initiated RUXCOVID, a Phase 3 clinical trial, and an Expanded Access Program with ruxolitinib.
Learn more
Therapeutics
inflaRx
InflaRX is investigating the safety and efficacy of IFX-1, the company´s monoclonal anti-C5a antibody.
Learn more
Therapeutics
INOVIO
INOVIO is developing its DNA vaccine INO-4800 to address COVID-19.
Learn more
Vaccines
InveniAI
InveniAI has identified over 100 drug candidates that could be repurposed to treat COVID-19.
Learn more
Therapeutics
J&J
J&J has moved to Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate. 
Learn more
Vaccines
Karyopharm
Karyopharm is evaluating low dose Selinexor as a potential treatment for hospitalized patients with COVID-19.
Learn more
Therapeutics
Laurent Pharmaceuticals
Laurent is testing LAU-7b in patients with COVID-19 disease, as part of a Phase 2 clinical trial.
Learn more
Therapeutics
Leading BioSciences
Leading BioSciences is investigating its lead drug, LB1148, for the treatment of coronavirus-associated ARDS and MODS.
Learn more
Therapeutics
Lilly
Lilly and AbCellera agreed to co-develop antibody products for the treatment and prevention of COVID-19.
Learn more
Diagnostics
Medicago
Medicago has produced a Virus-Like Particle (VLP) of the coronavirus which will be tested for safety and efficiency.
Learn more
Vaccines
Merck
Merck is pursuing multiple pathways and collaborating with others to study a range of medicines and vaccines to end COVID-19. 
Learn more
Vaccines
Mesoblast
Mesoblast is evaluating its MSC product candidate remestemcel-L in patients with ARDS caused by COVID-19.
Learn more
Therapeutics
Moderna
Moderna has developed the vaccine candidate mRNA-1273.
Learn more
Vaccines
Nabriva
Nabriva is preparing for the potential need for widespread CABP and XENLETA treatment to treat COVID-19.
Learn more
Therapeutics
Novartis
Novartis is joining a range of collaborative R&D efforts to respond to COVID-19.
Learn more
Therapeutics
Novavax
Novavax has produced NVX-CoV2373, a vaccine candidate that is designed to provide protection against COVID-19.
Learn more
Vaccines
Orgenesis
Orgenesis is collaborating with Leidos to develop Orgenesis’ Ranpirnase for the treatment of patients suffering with COVID. 
Learn more
Therapeutics
Paratek
Paratek has submitted a pre-EUA application to FDA for NUZYRA for treatment of COVID-19. 
Learn more
Therapeutics
Partner Therapeutics
Partner Therapeutics has initiated a clinical trial to evaluate Leukine® in patients with COVID-19 associated respiratory illness.
Learn more
Therapeutics
patheon
Thermo-Fisher Scientific expand to support the development and production of therapeutics and vaccines.
Learn more
Therapeutics
Pfizer
Pfizer is codeveloping BioNTech's mRNA-based vaccine candidate, BNT162, to prevent COVID-19.
Learn more
Vaccines
PharmaMar
PharmaMar is testing the use of Aplidin® (plitidepsin) for the treatment of COVID-19.
Learn more
Therapeutics
Premas
Premas is continuing research on Viral Surface proteins to find a potential candidate for developing vaccines.
Learn more
Therapeutics
RedHill Biopharma
RedHill Biopharma is testing the use of Opaganib for COVID-19.
Learn more
Therapeutics
Regeneron
Regeneron is developing antibodies and evaluating one of its existing medicines for the prevention and treatment of COVID-19. 
Learn more
Therapeutics
Roche
Roche is working to increase the availability of COVID-19 tests and is testing Actemra's potential utility in COVID-19 pneumonia patients. 
Learn more
Diagnostics
Roivant
Roviant is evaluating the use of gimsilumab in COVID-19 patients for the prevention and treatment of ARDS.   
Learn more
Therapeutics
SAB
SAB Biotherapeutics is generating targeted human polyclonal antibodies for therapeutics and diagnostics. 
Learn more
Therapeutics
Sanofi
Sanofi is working on vaccine development and researching existing products as potential treatments for COVID-19.
Learn more
Therapeutics
Sarepta
Sarepta Therapeutics is evaluating multiple constructs from its proprietary RNA platform as potential treatments for COVID-19. 
Learn more
Therapeutics
Seqirus
Seqirus is donating adjuvant technology, MF59® to a pre-clinical development program. 
Learn more
Vaccines
Southern Research
Southern Research Institute is co-developing the candidate vaccine TNX-1800.
Learn more
Vaccines
Synairgen
Synairgen is conducting a trial of SNG001 in COVID-19 patients.
Learn more
Therapeutics
Takeda
Takeda is developing a blood plasma-derived therapy to potentially treat COVID-19.
Learn more
Therapeutics
Tonix
Tonix Pharmaceuticals is co-developing the candidate vaccine TNX-1800.
Learn more
Vaccines
UCB
UCB is working to identify crystal structures of SARS-CoV-2 proteins in response to COVID-19.
Learn more
Therapeutics
Valenva
Valneva has reached agreement in principle with the UK government to provide up to 100 million doses of its SARS-CoV-2 vaccine candidate.
Learn more
Vaccines
Vanda
Vanda has initiated the clinical study of ODYSSEY VLY-686-3501 in hospitalized patients with COVID-19.
Learn more
Therapeutics
Vaxart
Vaxart has produced five COVID-19 vaccine candidates for testing in its preclinical models.
Learn more
Vaccines
VBI Vaccines
VBI Vaccines is developing a pan-coronavirus vaccine candidate, targeting COVID-19.
Learn more
Vaccines
VIR
Vir is manufacturing human monoclonal antibodies as a potential treatment to COVID-19.
Learn more
Therapeutics

https://www.bio.org/policy/human-health/vaccines-biodefense/coronavirus


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities